Kidney Cancer Research: Andrew Schmidt, MBBS presents a study that identifies a very favorable risk group in advanced kidney cancer patients treated with first-line therapy. ASCO #GU21 abstract 339.
prognostic criteria are important that help inform our treatment decisions in the clinic and help with risk discussions for patients with metastatic kidney cancer. And what we sought to do is to see if we could define a very favorable rescript. So patients who have a more favor or indolent disease course. And so we looked at the favorable risk group within the MDC dataset, which is a big multinational database which has been set up for patients with kidney cancer and sought to define criteria that would define patients with a very favorable risk disease. And what we found is that we found three criteria, which was the time from diagnosis to when patients start therapy. They're karnowski performance status, and the sites of metastatic disease were able to discriminate a very favorable risk cohort of patients. And they demonstrated a more indolent disease course and had to prolong survival compared to favorable risk patients. And so the significance here is that there are ways to define it baseline using clinical and laboratory drew features. Um, what could define a more favorable risk group of patients and what we're trying to do now is study the underlying disease, biology to see if we can discriminate on a cellular level. What causes this different prognosis and also validate this in an external data set? So try and see whether the findings can be replicated in another population of patients. And with that, we're hoping to both duplicate the results to see that they are validated in that external data set, Um, and then to move forward to see if there are then treatment decisions, which might be different in patients based on what we do.
